EpiCept Corp. is discontinuing all drug discovery activities and reducing its workforce by approximately 65%. These actions are expected to reduce annual expenses by at least $5.5 million. EpiCept will direct its resources toward the registration of Ceplene in North America and clinical development programs.  “This is a difficult decision and is largely attributable to the current financing environment, but in taking these actions we will help ensure that EpiCept has the resources to execute...